Idenix Pharmaceuticals (IDIX)

[go seek]

First big bump for Tyzeka:

3/30: 87 NRx, 142 TRx; 3.9% new, 2.0% total
3/23: 55 NRx, 90 TRx; 2.7% new, 1.3% total
2/23: 59 NRx, 92 TRx; 3.1% new, 1.4% total
2/9: 55 NRx, 83 TRx; 2.6% new, 1.2% total
1/26: 41 NRx, 60 TRx; 2.0% new, 0.9% total

The "new" figure refers to Tyzeka’s market share in the given week among new prescriptions for all HBV drugs.

The "total" figure refers to Tyzeka’s market share in the given week among total prescriptions—new and refills—for all HBV drugs.

For a recently-launched drug such as Tyzeka, the market share of new prescriptions is a more useful gauge than the market share of total prescriptions.